A decade with whole exome sequencing in haematology

Publikation: Bidrag til tidsskriftReviewForskningpeer review

Resumé

The first decade of capture-based targeted whole exome sequencing (WES) has now passed, while the sequencing modality continues to find more widespread usage in clinical research laboratories and still offers an unprecedented diagnostic assay in terms of throughput, informational content and running costs. Until quite recently, WES has been out of reach for many clinicians and molecular biologists, and it still poses issues or is met with some reluctance with regards to cost versus benefit in terms of effective assay costs, hands-on laboratory work and data analysis bottlenecks. Although WES is used more than ever, it may also be argued that the usage is peaking and that new implementations, or relevance in its current state, will likely be leveling off during the following decade as the price on whole genome sequencing continues to drop. In this review, we focus on the past decade of targeted whole exome sequencing in malignant hematology. We thematically revisit some of the significant discoveries and niches that use next-generation sequencing, and we outline what and how WES has contributed to the field - from clonal hematopoiesis of the aging bone marrow to profiling malignancies down to the single cell.

OriginalsprogEngelsk
TidsskriftBritish journal of haematology
Vol/bind188
Udgave nummer3
Sider (fra-til)367-382
ISSN0007-1048
DOI
StatusUdgivet - feb. 2020

Fingeraftryk

Exome
Hematology
Cost-Benefit Analysis
Research
Neoplasms

Bibliografisk note

© 2019 British Society for Haematology and John Wiley & Sons Ltd.

Citer dette

@article{c52f0f6436ee48b98061dc1b36fc4752,
title = "A decade with whole exome sequencing in haematology",
abstract = "The first decade of capture-based targeted whole exome sequencing (WES) has now passed, while the sequencing modality continues to find more widespread usage in clinical research laboratories and still offers an unprecedented diagnostic assay in terms of throughput, informational content and running costs. Until quite recently, WES has been out of reach for many clinicians and molecular biologists, and it still poses issues or is met with some reluctance with regards to cost versus benefit in terms of effective assay costs, hands-on laboratory work and data analysis bottlenecks. Although WES is used more than ever, it may also be argued that the usage is peaking and that new implementations, or relevance in its current state, will likely be leveling off during the following decade as the price on whole genome sequencing continues to drop. In this review, we focus on the past decade of targeted whole exome sequencing in malignant hematology. We thematically revisit some of the significant discoveries and niches that use next-generation sequencing, and we outline what and how WES has contributed to the field - from clonal hematopoiesis of the aging bone marrow to profiling malignancies down to the single cell.",
keywords = "laboratory hematology, next generation sequencing, sequencing anniversary, targeted panel sequencing, whole exome sequencing, whole genome sequencing",
author = "Hansen, {Marcus C} and Torsten Haferlach and Nyvold, {Charlotte G}",
note = "{\circledC} 2019 British Society for Haematology and John Wiley & Sons Ltd.",
year = "2020",
month = "2",
doi = "10.1111/bjh.16249",
language = "English",
volume = "188",
pages = "367--382",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "3",

}

A decade with whole exome sequencing in haematology. / Hansen, Marcus C; Haferlach, Torsten; Nyvold, Charlotte G.

I: British journal of haematology, Bind 188, Nr. 3, 02.2020, s. 367-382.

Publikation: Bidrag til tidsskriftReviewForskningpeer review

TY - JOUR

T1 - A decade with whole exome sequencing in haematology

AU - Hansen, Marcus C

AU - Haferlach, Torsten

AU - Nyvold, Charlotte G

N1 - © 2019 British Society for Haematology and John Wiley & Sons Ltd.

PY - 2020/2

Y1 - 2020/2

N2 - The first decade of capture-based targeted whole exome sequencing (WES) has now passed, while the sequencing modality continues to find more widespread usage in clinical research laboratories and still offers an unprecedented diagnostic assay in terms of throughput, informational content and running costs. Until quite recently, WES has been out of reach for many clinicians and molecular biologists, and it still poses issues or is met with some reluctance with regards to cost versus benefit in terms of effective assay costs, hands-on laboratory work and data analysis bottlenecks. Although WES is used more than ever, it may also be argued that the usage is peaking and that new implementations, or relevance in its current state, will likely be leveling off during the following decade as the price on whole genome sequencing continues to drop. In this review, we focus on the past decade of targeted whole exome sequencing in malignant hematology. We thematically revisit some of the significant discoveries and niches that use next-generation sequencing, and we outline what and how WES has contributed to the field - from clonal hematopoiesis of the aging bone marrow to profiling malignancies down to the single cell.

AB - The first decade of capture-based targeted whole exome sequencing (WES) has now passed, while the sequencing modality continues to find more widespread usage in clinical research laboratories and still offers an unprecedented diagnostic assay in terms of throughput, informational content and running costs. Until quite recently, WES has been out of reach for many clinicians and molecular biologists, and it still poses issues or is met with some reluctance with regards to cost versus benefit in terms of effective assay costs, hands-on laboratory work and data analysis bottlenecks. Although WES is used more than ever, it may also be argued that the usage is peaking and that new implementations, or relevance in its current state, will likely be leveling off during the following decade as the price on whole genome sequencing continues to drop. In this review, we focus on the past decade of targeted whole exome sequencing in malignant hematology. We thematically revisit some of the significant discoveries and niches that use next-generation sequencing, and we outline what and how WES has contributed to the field - from clonal hematopoiesis of the aging bone marrow to profiling malignancies down to the single cell.

KW - laboratory hematology

KW - next generation sequencing

KW - sequencing anniversary

KW - targeted panel sequencing

KW - whole exome sequencing

KW - whole genome sequencing

U2 - 10.1111/bjh.16249

DO - 10.1111/bjh.16249

M3 - Review

C2 - 31602633

VL - 188

SP - 367

EP - 382

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -